Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade
Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, im...
This Healthy High-Yielding Dividend Stock Just Increased Its Payment for the 48th Year in a Row
Medtronic (MDT -4.12%) has been a dividend stalwart for decades. The medical device maker recently raised its dividend payment, extending its growth streak to 48 straight years.
'WIN-WIN': Medtronic CEO explains the reason for diabetes biz spin
Medtronic chairman and CEO Geoff Martha explains why the company is separating the diabetes business on 'The Claman Countdown.' #foxbusiness #usnews #economy #investing #diabetes #health #markets
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland , May 21, 2025 /PRNewswire/ -- Medtronic p...
Medtronic announces intent to separate Diabetes business
Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only ...
Medtronic to separate diabetes business, WSJ reports
Medical device maker Medtronic plans to separate its diabetes business into a stand-alone company, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Medtronic to Separate Diabetes Business
The medical device maker has been working to turn around the division over the last few years.
Will Medtronic's Earnings Move The Stock?
Medtronic (NYSE:MDT) is scheduled to announce its earnings on Wednesday, May 21, 2025. Over the last five years, Medtronic's stock has shown a favorable one-day return following its earnings announ...
What Analyst Projections for Key Metrics Reveal About Medtronic (MDT) Q4 Earnings
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...
This Magnificent High-Yield Dividend Stock Just Became an Even Better Buy
Medical device specialist Medtronic (MDT 1.38%) has not performed well over the past five years; the stock has significantly lagged broader equities. One of the issues it's encountered is slow reve...
Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-ener...
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years
Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility. In fact, it's still a great time to invest ...
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system
Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Assoc...
Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical ...
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Lat...
Medtronic (MDT) Rises But Trails Market: What Investors Should Know
The latest trading day saw Medtronic (MDT) settling at $83.75, representing a +0.46% change from its previous close.
Related Companies